For 176 postmenopausal women on HRT with progestogen addition 'on demand' medroxyprogesterone acetate (MPA), noresthisterone and tibolone were used to protect the endometrium in 214 cases. Tibolone is a gonadomimetic steroid with combined progestogenic and estrogenic effects. In this study tibolone has been used as a progestogen. The results of these three progestogens were compared. The endometrial thickness before and after the use of progestogen was determined by vaginosonography. In 175 out of 214 cases progestogen addition during oestrogen therapy caused endometrial regression. Withdrawal bleeding was observed 166 times. If the endometrial thickness on the onset of progestogen addition was 5 mm or more, in nearly all cases withdrawal bleeding occurred when MPA or norethisterone was used. If tibolone was used, no withdrawal bleeding occurred in over half the cases studied. We report the first observation of induced endometrial regression without withdrawal bleeding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0378-5122(94)00867-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factor XIa Inhibitor Reversal in Intracranial Hemorrhage: A Case Report.
Neurohospitalist
January 2025
Department of Neurology, Division of Neurocritical Care, University of North Carolina, Chapel Hill, NC, USA.
Background/objectives: There is currently no consensus regarding the optimal strategy for reversal of anticoagulation in life-threatening hemorrhage associated with factor XIa (FXIa) inhibitors.
Methods: For this clinical case report, informed consent was obtained from surrogate.
Results And Discussion: Here, we present the case of an 82-year-old female who sustained a large subdural hematoma after a fall.
A Case of Familial Mediterranean Fever With Severe Attacks During Withdrawal Bleeding After Controlled Ovarian Hyperstimulation.
Cureus
December 2024
Department of Obstetrics and Gynecology, Shiga University of Medical Science, Ostu, JPN.
Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by periodic fever, serositis, and arthritis. In women, FMF attacks can sometimes be triggered by the menstrual cycle. Once diagnosed, prophylactic treatment with colchicine is generally recommended.
View Article and Find Full Text PDFFolic acid allergy in pregnancy: a case report.
J Pak Med Assoc
January 2025
Department of Obstetrics and Gynaecology, Ajman University, Ajman, UAE.
Folic acid intake prevents neural tube defects in the developing foetus. Folic acid allergy in pregnancy is very rare. Most physicians are unaware of this complication.
View Article and Find Full Text PDFAspirin-free strategies after percutaneous coronary intervention: Old habits, consolidated evidence and future perspectives.
Eur J Intern Med
January 2025
Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
For almost two decades, dual antiplatelet therapy (DAPT) has been considered the cornerstone of pharmacological treatment in patients undergoing percutaneous coronary intervention (PCI). DAPT composition and duration have considerably evolved in the last decade moving from fixed treatment durations to tailored strategies based on the individual ischemic and bleeding risks. The increasing awareness of the prognostic relevance of bleeding events after PCI and the need for tailoring DAPT according to the individual bleeding and ischemic risks paved the way to newer DAPT modulation strategies by early aspirin withdrawal which have been shown to decrease bleeding without affecting therapeutic efficacy.
View Article and Find Full Text PDFPembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial.
Lancet Oncol
January 2025
Department of Haematology-Oncology, National University Cancer Institute, Singapore; Department of Pharmacology, National University of Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore. Electronic address:
Background: Vascular endothelial growth factor (VEGF) is overexpressed in nasopharyngeal carcinoma and suppresses the anti-tumour immune response. Previous studies have shown that adding anti-VEGF treatment to PD-1 inhibition treatment strategies improves tumour response. We aimed to compare the efficacy of pembrolizumab, a PD-1 inhibitor, with or without bevacizumab, a VEGF inhibitor, in nasopharyngeal carcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!